Phone: (707) 546-5553
Email Us
1140 Sonoma Avenue 1-A
Santa Rosa, CA 95405

Monthly Archives: April 2016

Santa Rosa Urologist Dr. Michael Lazar is Making History with a Nonsurgical, Outpatient Treatment for Prostate Cancer

Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU.

Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU.

High-intensity focused ultrasound (HIFU) waves target cancer cells with precision in a one-to-four-hour procedure that has little or no side affects and a quick recovery rate, giving those diagnosed with prostate cancer another choice over surgery or radiation.

HIFU has been used in other countries for years, and Dr. Lazar has been instrumental in bringing this innovative treatment to the United States. It was approved by the Food and Drug Administration last October, and he has since been performing the procedure at San Francisco Surgery Center for patients who travel from across the country to receive this leading edge treatment.

“The oncological results for HIFU are broadly comparable to radical surgery or radiation but the side effects are less,” says Dr. Lazar. “If the HIFU procedure is performed in the morning, a patient is typically up and around by dinnertime and can often return to normal activity within a few days without the use of pain-killers.”

Dr. Lazar has recently become involved with HIFU Prostate Services, LLC as their Medical Director.  HIFU Prostate Services is the first company to establish centers in the United States offering Sonablate HIFU technology. HIFU Prostate Services makes the non-invasive treatment option available through partnerships with some of the largest urology practices and experienced physicians that establish Sonablate HIFU Centers of Excellence.  Urologists are able to create their own HIFU program and offer treatment within their region. These centers also offer training and proctorship opportunities.

Along with serving as the Medical Director of HIFU Prostate Services, LLC. Dr. Lazar is also a clinical partner with his HIFU Center of Excellence at the state-of-the-art SFSC in downtown San Francisco. Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU. He has worked tirelessly with SonaCare, the manufacturer of the instruments, to bring this innovative service for prostate cancer treatment to patients in the United States.

The HIFU technique is also being developed to treat many other types of cancer including breast, uterine, liver, kidney, and brain.

For those with prostate cancer, HIFU treatment is most effective for patients with early stage cancer, where it is localized to the prostate. It is performed on an out-patient basis that takes one to four hours. A urinary catheter is placed after the procedure for one to three weeks.

While some patients might experience slight irritation, “some patients can have a catheter and they don’t even know it.”

The procedure preserves healthy tissue and nerves, so urine flow and erectile function is maintained in a high percent of cases, as compared to radical surgery or radiation.

Another advantage is recovery time. With surgery or radiation treatment, recuperation time for patients is six to eight weeks, whereas HIFU patients return to normal activities within days.

Dr-michael-lazarDr. Lazar has been treating U.S. prostate cancer patients in Mexico since 2007, where he performed hundreds of outpatient procedures at a U.S. Joint Commission approved bilingual hospital. There, he also served as a HIFU instructor for other physicians and is now training doctors in San Francisco.

Because the treatment is so new, it will take another couple of years before it will be routinely covered by insurance. Those with non-Medicare insurance may get reimbursed to varying degrees.

“What will really make this explode is when the insurance companies are routinely covering the procedure and it will become widely available to all patients. The costs for this procedure are drastically less than for radical surgical and radiation procedures, and with fewer complications so insurance companies will be incentivized to cover it,” Dr. Lazar commented.

As soon as more doctors are trained to perform the procedure in San Francisco, Dr. Lazar plans to bring the treatment to his Santa Rosa office.

“I expect as word gets out there will be a progressive demand for this procedure, so training physicians will be a high priority. It’s already expanding rapidly and we put in an order for our tenth machine,” said Dr. Lazar, adding he won’t be giving up his general urology practice any time soon. “This is what I love to do.”

 

 

 

New Study Reveals Prostate Cancer Metastasis Risk Higher in Some AS Patients

Metastases develop in a small proportion of patients placed on active surveillance (AS) for prostate cancer (PCa), but the risk is significantly higher in some men than others, such as those with Gleason 7 tumors, a new study found.

In a study of 980 men placed on AS—769 with low-risk and 211 with intermediate-risk PCa—a team led by Laurence Klotz, MD, of Sunnybrook Health Sciences Centre in Toronto found that 30 men (3%) progressed to metastatic disease at a median of 6.3 year after diagnosis, according to study findings published in The Journal of Urology (2016;195:1409-1414). Metastases developed in 13 (10%) of 133 patients with Gleason 7 disease.

Metastases occurred in 16 low-risk and 14 intermediate-risk patients, and developed in bone in 18 patients and lymph nodes in 13. Of the 30 men, 15 died from PCa, 4 died of other causes, and 11 are alive with metastases.

Patients with intermediate-risk disease were at higher risk for metastasis, but those with Gleason score 6 and PSA level greater than 10 ng/mL were not at increased risk.

In multivariate analysis, a PSA doubling time less than 3 years versus greater than 3 years was associated with a 3.7-fold increased risk of metastasis. Gleason score 7 compared with 6 was associated with a 3-fold increased risk. The presence of 3 or more positive biopsy cores was associated with a 2.7-fold increased risk compared with fewer positive cores.

The authors concluded that AS appears safe in patients at low risk and in select patients at intermediate risk, particularly those with Gleason score 6 and PSA levels greater than 10 ng/mL. The presence of Gleason pattern 4 on diagnostic biopsy was associated with a 3-fold to 4-fold increased risk of metastasis. Patients with Gleason pattern 4 should be offered active surveillance with caution, according to the investigators.

In editorial comments accompanying the new report, Michael O. Koch, MD, of the Indiana University School of Medicine in Indianapolis, said Dr. Klotz and his colleagues contribute to the growing body of knowledge of the usefulness of AS for managing PCa, but observed: “While the authors have highlighted the risk factors for developing metastases in patients treated with AS, they may be overly optimistic about the safety of this management strategy, particularly in patients with Gleason 7 disease.”

Dr. Koch pointed out that the median follow-up was only 6.3 years, so the number of patients with Gleason 7 disease in whom metastases will develop will grow even more. “As of now AS would appear to be ill-advised in this group of patients,” he noted.

Source: http://www.renalandurologynews.com

For more information about HIFU treatment which is now available in San Francisco, or to make an appointment call: (707) 546-5553. Visit us online to learn more at: www.californiahifu.com

See this article on Renal & Urology News …

By | April 13th, 2016|HIFU, News, Urology|0 Comments

HIFU San Francisco – Meet Dr. Michael Lazar

HIFU 4.12 pic 1.2Michael J. Lazar, MD was an early user of the HIFU technology dating back to 2007.  He was credentialed as proctor in 2010 and participated in editing the user manual for the Sonablate HIFU system. Lazar trained FDA investigators on HIFU patient care and was commissioned by SonaCare Medical to proctor FDA clinical trial cases.  He has treated or been involved with over 200 patients and is also site director for SonaCare Medical’s international training site in Puerto Vallarta, Mexico.

Dr. Lazar has been certified by the American Board of Urology four times and has practiced in Santa Rosa, Calif. since 1983.  He is chairman of the Board of Redwood Health Services, Inc. providing insurance products for employee groups. Dr. Lazar is also CEO and managing director of Santa Rosa Surgical Management Company, LLC that manages the ambulatory surgery center at Santa Rosa Memorial Hospital.  He has participated in medical staff leadership and has served as hospital chief-of-staff and well as departmental and section chairs.  Dr. Lazar received his urology training at Louisiana State University in New Orleans, La. and is a graduate of University of Arkansas Medical School.

California HIFU

Dr. Lazar formed California HIFU in order to offer minimally invasive prostate cancer treatment to men with the Sonablate. He performs HIFU at HIFU Center of Excellence In San Francisco, 450 Sutter Street, Suite 500, San Francisco, CA 94108

HIFU Center of Excellence offers patients a state-of-the-art facility in downtown that is convenient to hotels and the airport for patients interested in traveling from around the country for this recently FDA-cleared treatment. For more information about HIFU treatment which is now available in San Francisco, or to make an appointment call: (707) 546-5553. Visit us online to learn more at: www.californiahifu.com

See more on the HIFU Prostate Services website.

By | April 12th, 2016|Dr. Michael Lazar, HIFU, News|0 Comments

HIFU Center of Excellence in San Francisco

HIFU 4.12 pic 1Sonablate HIFU is available now with Dr. Michael Lazar at HIFU Center of Excellence In San Francisco located in downtown San Francisco, 450 Sutter Street, Suite 500, San Francisco, CA 94108

HIFU Center of Excellence offers patients a state-of-the-art facility in downtown that is convenient to hotels and the airport for patients interested in traveling from around the country for this recently FDA-cleared treatment. For more information about HIFU treatment which is now available in San Francisco, or to make an appointment call: (707) 546-5553. Visit us online to learn more at: www.californiahifu.com

HIFU 4.12 pic 1.2Physician Practicing HIFU in San Francisco: Dr. Michael Lazar

See more on the HIFU Prostate Services Website.

By | April 12th, 2016|Dr. Michael Lazar, HIFU, News|0 Comments

Prostate cancer treatment which avoids harming sexual performance soon available on NHS

A revolutionary prostate cancer treatment which avoids harming men’s sexual performance could soon be available on the NHS.

High Intensity Focused Ultrasound kills the tumour with heat without damaging healthy tissue around it.

In an NHS trial led by University College Hospital, London, 625 men were treated. After five years 93% were cancer-free.

Only 15% had erectile problems compared with 30 to 60% following surgery.

The results were revealed to the European Association of Urology in Munich.

 

Read the full story …

By | April 5th, 2016|HIFU, News, Prostate Cancer, Testimonials|0 Comments